PerkinElmer, Inc. today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC. PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.
Prahlad Singh, President and CEO at PerkinElmer said, “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT®.TB test, and the operations it has built are remarkable. We recognize the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”
Based in Abingdon, UK, Oxford Immunotec is a global leader in the field of proprietary test kits for latent tuberculosis. Oxford Immunotec had approximately 275 employees as of September 30, 2020 and reported total revenue from continuing operations of $73.74 million for the fiscal year ended December 31, 2019.